A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression

British Journal of Haematology

Volumn 121, Issue 4, 2003, Pages 578-585

  Giles, Francis J ^a   Bekele, B Nebiyou ^a   O'Brien, Susan ^a   Cortes, Jorge E ^a   Verstovsek, Srdan ^a   Balerdi, Maria ^a   Yared, Marwan ^a   Zhou, Xian ^a   Kantarjian, Hagop M ^a   Keating, Michael J ^a   Thall, Peter ^a   Albitar, Maher ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic lymphocytic leukaemia; Immunoperoxidase; p53; Prognosis; Survival

Indexed keywords

BETA 2 MICROGLOBULIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER GRADING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION COEFFICIENT; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REPRODUCIBILITY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037716441     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04306.x     Document Type: Article

References (26)

1. Aguilar-Santelises, M., Magnusson, K.P., Wiman, K.G., Mellstedt, H. & Jondal, M. (1994) Progressive B-cell chronic lymphocytic leukaemia frequently exhibits aberrant p53 expression. International Journal of Cancer, 58, 474-479.
2. Bartek, J., Bartkova, J., Vojtesek, B., Staskova, Z., Lukas, J., Rejthar, A., Kovarik, J., Midgley, C.A., Gannon, J.V. & Lane, D.P. (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene, 6, 1699-1703.
3. Bullock, A.N. & Fersht, A.R. (2001) Rescuing the function of mutant p53. Nature Review of Cancer, 1, 68-76.
4. Cordone, I., Masi, S., Mauro, F.R., Soddu, S., Morsilli. O.. Valentini, T., Vegna, M.L., Guglielmi, C., Mancini, F., Giuliacci, S., Sacchi, A., Mandelli, F. & Foa, R. (1998) p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood, 91, 4342-4349.
5. De Angeli C., Gandini, D., Cuneo, A., Moretti, S., Bigoni, R., Roberti, M.G., Bardi, A., Castoldi, G.L. & del Senno, L. (2000) BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13:q32). Haematologica, 85, 913-921.
6. Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J. & Stilgenbauer, S. (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood, 85, 1580-1589.
7. Fenaux, P., Preudhomme, C., Lai, J.L., Quiquandon, I., Jonveaux, P., Vanrumbeke, M., Sartiaux, C., Morel, P., Loucheux-Lefebvre, M.H. & Bauters, F. (1992) Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia, 6, 246-250.
8. Gaidano, G., Ballerini, P., Gong, J.Z., Inghirami, G., Neri, A., Newcomb, E.W., Magrath, I.T., Knowles, D.M. & Dalla-Favera, R. (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 88, 5413-5417.
9. Gandini, D., Aguiari, G.L., Cuneo, A., Piva, R., Castoldi, G.L. & del Senno, L. (1994) Novel small deletions of the p53 gene in late-stage B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 88, 881-885.
10. Gannon, J.V., Greaves, R., Iggo, R. & Lane, D.P. (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO Journal. 9, 1595-1602.
11. Grambsch, P.M. (1995) Goodness-of-fit and diagnostics for proportional hazards regression models. Cancer Treatment Research, 75, 95-112.
12. Grambsch, P.M., Therneau, T.M. & Fleming, T.R. (1995) Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics, 51, 1469-1482.
13. Lane, D.P. (1992) p53, guardian of the genome. Nature, 358, 15-16.
14. Lepelley, P., Preudhomme, C., Vanrumbeke, M., Quesnel, B., Cosson, A. & Fenaux, P. (1994) Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia, 8, 1342-1349.
15. Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell, 88, 323-331.
16. Lin, K., Sherrington, P.D., Dennis, M., Matrai, Z., Cawley, J.C. & Pettitt, A.R. (2002) Relationship between p53 dysfunction, CD38 expression, anal IgV(H) mutation in chronic lymphocytic leukemia. Blood, 100, 1404-1409.
17. O'Brien, S. (2001) NCCN: new directions in chronic lymphocytic leukemia. Cancer Control, 8, 114-117.
18. O'Brien, S., Kantarjian, H., Beran, M., Smith, T., Koller, C., Estey, E., Robertson, L.E., Lerner, S. & Keating, M. (1993) Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood, 82, 1695-1700.
19. O'Brien, S.M., Kantarjian, H.M., Cortes, J., Beran, M., Koller, C.A., Giles, F.J., Lerner, S. & Keating, M. (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology, 19, 1414-1420.
20. Oscier, D.G., Gardiner, A.C., Mould, S.J., Glide, S., Davis, Z.A., Ibbotson, R.E., Corcoran, M.M., Chapman, R.M., Thomas, P.W., Copplestone, J.A., Orchard, J.A. & Hamblin, T.J. (2002) Multi-variate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood, 100, 1177-1184.
21. Pollack, I.F., Finkelstein, S.D., Woods, J., Burnham, J., Holmes, E.J., Hamilton, R.L., Yates, A.J., Boyett, J.M., Finlay, J.L. & Sposto, R. (2002) Expression of p53 and prognosis in children with malignant gliomas. New England Journal of Medicine, 346, 420-427.
22. el Rouby, S., Thomas, A., Costin, D., Rosenberg, C.R., Potmesil, M., Silber, R. & Newcomb, E.W. (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood, 82, 3452-3459.
23. Thall, P.F. & Estey, E.H. (2001) Graphical methods for evaluating covariate effects in the Cox model. In: Handbook of Statistics in Clinical Oncology (ed. by J. Crowley), pp. 411-432. Marcel Dekker, New York.
24. Venables, W.N. & Ripley, B.D. (1999) Modern Applied Statistics with S-Plus 3rd edn. Springer, New York.
25. Vousden, K.H. (2002) Activation of the p53 tumor suppressor protein. Biochemica Biophysics Acta, 1602, 47-59.
26. Zwiebel, J.A. & Cheson, B.D. (1998) Chronic lymphocytic leukemia: staging and prognostic factors. Seminars in Oncology, 25, 42-59.